Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada...
and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
Stockoman1
X
View Profile
View Bullboard History
Post by
Stockoman1
on Dec 22, 2023 9:18am
Interesting things going on....
https://www.theglobeandmail.com/investing/markets/stocks/GUD-T/pressreleases/22829458/
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Dec 19, 2023 11:00am
Qelbree - ADHD - huge opportunity
ADHD - more & more kids are affected by this & stand to benefit from a great therapeutic
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 23, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Dec 07, 2023 9:43am
Abbvie buying Cerevel for $8.7B
A huge premium (~73%) to stock price. showing lots of interest in industry following previous $10b purchase in oncology
(14)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Nov 30, 2023 10:33am
RE:Ardelyx, portalix biotherapeutics taking off today
The Ardelyx drug is now doing about a million per year in sales for us. The relative growth rate is nice but in absolute numbers it's still quite low. According to Ardelyx's latest 10-K, we
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 30, 2023 9:44am
Abbie to buy Immunogenicity for $10.1 Billion
On ovarian cancer drug. great for medical /pharma advances and shows how great value exists in the space. & opportunity... & need for global distribution partners
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 29, 2023 2:04pm
Ardelyx, portalix biotherapeutics taking off today
Investments still held by Knight?
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 09, 2023 8:27pm
A respectable quarter for sure!
Yes. A respectable quarter! We are seeing the team execute on multiple fronts . I think Samira even said how the current products are growing in lots of regions &
...more
(188)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Nov 09, 2023 2:42pm
RE:Update on Portfolio's Peak Potential
Finally a respectable quarter and some decent guidance! I have much higher expectations for Knight in 2024 than 2023. The platform must continue to grow and be profitable.
(14)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Nov 09, 2023 9:28am
Update on Portfolio's Peak Potential
Potential yearly combined sales went from $50M-$75M to $70-$100M.
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 09, 2023 8:26am
Great quarter
Great numbers all around, including record revenue,
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 09, 2023 7:30am
New Press Release - Knight Therapeutics Reports Third Quarter 2023 Results
- Achieved Record Nine-month Revenues and Adjusted EBITDA MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended...
read article.
(14)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Nov 09, 2023 4:30am
Buybacks
During the past three months, GUD has bought back around 2.4 million shares. Relative to outstanding shares, this is the highest pace for buybacks we've had. If my numbers are correct:
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 02, 2023 7:30am
New Press Release - Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Following the release, Knight...
read article.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Oct 29, 2023 3:23pm
RE:Jeff Martens
If I were to guess - and only a guess ... There is a very high level of expectation from Management. There is nowhere to hide and you must always be at the top of your game. You are either
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth